Jonathan Back
Overview
Explore the profile of Jonathan Back including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manni M, Mantuano N, Zingg A, Kappos E, Behrens A, Back J, et al.
Front Immunol
. 2023 Dec;
14:1291292.
PMID: 38094289
Humans lack the enzyme that produces the sialic acid N-glycolyl neuraminic acid (Neu5Gc), but several lines of evidence have shown that Neu5Gc can be taken up by mammalian food sources...
2.
Wawrzyniak M, Morsy Y, Mladenov R, Tontodonati G, Turgay Y, Herwig S, et al.
J Crohns Colitis
. 2021 Feb;
15(9):1596-1601.
PMID: 33631789
Background And Aims: Antibodies targeting tumor necrosis factor-alpha [TNF-alpha] are a mainstay in the treatment of inflammatory bowel disease. However, they fail to demonstrate efficacy in a considerable proportion of...
3.
Baker K, Hanrath A, van der Loeff I, Kay L, Back J, Duncan C
Clin Med (Lond)
. 2021 Feb;
21(2):84-89.
PMID: 33547065
Introduction: We sought to provide the first report of the use of NEWS2 monitoring to pre-emptively identify clinical deterioration within hospitalised COVID-19 patients. Methods: Consecutive adult admissions with PCR-confirmed COVID-19...
4.
Iacovides I, Blandford A, Cox A, Back J
Cogn Technol Work
. 2020 May;
18(4):793-805.
PMID: 32355464
Human error can have potentially devastating consequences in contexts such as healthcare, but there is a rarely a simple dichotomy between errors and correct behaviour. Furthermore, there has been little...
5.
Guttman-Yassky E, Pavel A, Zhou L, Estrada Y, Zhang N, Xu H, et al.
J Allergy Clin Immunol
. 2019 Feb;
144(2):482-493.e7.
PMID: 30738171
Background: GBR 830 is a humanized mAb against OX40, a costimulatory receptor on activated T cells. OX40 inhibition might have a therapeutic role in T cell-mediated diseases, including atopic dermatitis...
6.
Back J, Ross A, Duncan M, Jaye P, Henderson K, Anderson J
Ann Emerg Med
. 2017 Jul;
70(5):659-671.
PMID: 28662909
Study Objective: Escalation policies are used by emergency departments (EDs) when responding to an increase in demand (eg, a sudden inflow of patients) or a reduction in capacity (eg, a...
7.
Breton C, Nahimana A, Aubry D, Macoin J, Moretti P, Bertschinger M, et al.
J Hematol Oncol
. 2014 Apr;
7:33.
PMID: 24731302
Background: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B...
8.
Bessoles S, Angelov G, Back J, Leclercq G, Vivier E, Held W
J Immunol
. 2013 Oct;
191(10):5044-51.
PMID: 24098052
Although NK cells use invariant receptors to identify diseased cells, they nevertheless adapt to their environment, including the presence of certain MHC class I (MHC-I) molecules. This NK cell education,...
9.
Recovering from an interruption: investigating speed-accuracy trade-offs in task resumption behavior
Brumby D, Cox A, Back J, Gould S
J Exp Psychol Appl
. 2013 Jun;
19(2):95-107.
PMID: 23795978
Interruptions are disruptive because they take time to recover from, in the form of a resumption lag, and lead to an increase in the likelihood of errors being made. Despite...
10.
Back J, Angelov G, Mariuzza R, Held W
Front Immunol
. 2012 May;
2:55.
PMID: 22566845
Mouse natural killer (NK) cells express Ly49 family receptors that recognize major histocompatibility complex class I (MHC-I) molecules. By interacting with MHC-I molecules expressed on other cells (in trans), inhibitory...